摘要
[目的]利用层级虚拟筛选策略发掘潜在的cGAS-STING通路的干预剂。[方法]根据Human STING蛋白的结构特点,采用Virtual Screening Workflow模块进行虚拟筛选,选取Life Chemicals 50K Diversity Library(LC-50,含5万个化合物)和MCE Bioactive Compound Library Plus(MCE Library,含1.87万个化合物)作为配体库,并利用Glide模块进行分子对接筛选cGAS-STING通路的干预剂。[结果]分别从两个化合物库中筛选出对接分数绝对值最高的200个化合物,并综合脂水分配系数和拓扑极性表面积选出5个优选先导化合物F6286-0567、F6548-0970、F5098-0465、HY-N7269、HY-N0165,其对接分数分别为-11.097、-10.548、-6.237、-6.146、-5.959。脂水分配系数分别为3.57、3.97、4.08、3.61、3.74。拓扑极性表面积分别为76.29、80.13、75.19、82.19、69.72。[结论]筛选出的干预剂F6286-0567、F6548-0970、F5098-0465、HY-N7269、HY-N0165,在保证与Human STING蛋白的结合效果理想的同时,具有更好的细胞膜通过性和脂溶性,可能成为cGAS-STING通路潜在干预剂。
[Objective]Utilize a hierarchical virtual screening strategy to discover potential interveners for the cGAS-STING pathway.[Method]Based on the structural characteristics of the Human STING protein,the Virtual Screening Workflow module was employed for virtual screening.The Life Chemicals 50K Diversity Library(LC-50,containing 50,000 compounds)and MCE Bioactive Compound Library Plus(MCE Library,containing 18,700 compounds)were selected as ligand libraries.The Glide module was utilized for molecular docking to screen interveners for the cGAS-STING pathway.[Result]The top 200 compounds with the highest absolute docking scores were selected from each of the two compound libraries.Five preferred lead compounds,namely F6286-0567,F6548-0970,F5098-0465,HY-N7269,and HY-N0165,were chosen based on a combination of lipophilic water partition coefficient and topological polar surface area.Their docking scores were-11.097,-10.548,-6.237,-6.146,and-5.959,respectively.The lipophilic water partition coefficients were 3.57,3.97,4.08,3.61,and 3.74,while the topological polar surface areas were 76.29,80.13,75.19,82.19,and 69.72.[Conclusion]The screened interveners,F6286-0567,F6548-0970,F5098-0465,HY-N7269,and HY-N0165,exhibit ideal binding effects with the Human STING protein while possessing better cell membrane permeability and lipid solubility.These compounds have the potential to become interveners for the cGAS-STING pathway.
作者
黄鹤阳
浦飞飞
夏平
冯晶
HUANG Heyang;PU Feifei;XIA Ping;FENG Jing(The First Clinical College of Hubei University of Traditional Chinese Medicine,Wuhan 430065;Department of Orthopedics,Wuhan No.1 Hospital,Wuhan 430022;Department of Orthopedics,Affiliated Hospital of Integrated Traditional Chinese and Western Medicine,Hubei University of Chinese Medicine,Wuhan 430022;Department of Orthopedics,Wuhan Fourth Hospital,Wuhan 430030,China)
出处
《生物技术》
CAS
2024年第5期555-565,共11页
Biotechnology
基金
湖北省武汉卫生健康委员会重大项目(WX21M02)。